Aytu BioPharma, Inc. (AYTU)
NASDAQ: AYTU · Real-Time Price · USD
2.190
+0.290 (15.26%)
At close: Oct 6, 2025, 4:00 PM EDT
2.240
+0.050 (2.28%)
Pre-market: Oct 7, 2025, 4:01 AM EDT
Aytu BioPharma Revenue
In the fiscal year ending June 30, 2025, Aytu BioPharma had annual revenue of $66.38M with 1.84% growth. Aytu BioPharma had revenue of $15.14M in the quarter ending June 30, 2025, with 3.71% growth.
Revenue (ttm)
$66.38M
Revenue Growth
+1.84%
P/S Ratio
0.21
Revenue / Employee
$650,804
Employees
83
Market Cap
21.71M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 66.38M | 1.20M | 1.84% |
| Jun 30, 2024 | 65.18M | -8.62M | -11.67% |
| Jun 30, 2023 | 73.80M | -22.87M | -23.66% |
| Jun 30, 2022 | 96.67M | 31.04M | 47.29% |
| Jun 30, 2021 | 65.63M | 38.00M | 137.52% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
AYTU News
- 12 days ago - Aytu BioPharma to Present at Upcoming September 2025 Conferences - Accesswire
- 13 days ago - Aytu BioPharma, Inc. (AYTU) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Aytu BioPharma Reports Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results and Outlines Commercial Launch Plans for EXXUA(TM) - Accesswire
- 20 days ago - Aytu BioPharma to Report Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results on September 23, 2025 - Accesswire
- 3 months ago - Aytu BioPharma Appoints Dr. Gerwin Westfield as Senior Vice President of Scientific Affairs to Support Commercialization of EXXUA(TM) - Accesswire
- 3 months ago - Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA(TM) - Accesswire
- 4 months ago - Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA(TM) Opportunity and Commercialization Plan - Accesswire
- 4 months ago - Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock - Accesswire